The DOI matches its OpenAlex record; 1 of the 1 references it cites were found in a registry or an index.
Reduced Incidence of Gastroduodenal Ulcers With Celecoxib, A Novel Cyclooxygenase-2 Inhibitor, Compared To Naproxen in Patients With Arthritis
Abstract
OBJECTIVE: Nonsteroidal anti-inflammatory drugs (NSAIDs) block prostaglandin production by inhibiting cyclooxygenase (COX); they are believed to cause gastroduodenal damage by inhibiting the COX-1 isoform and to have analgesic and anti-inflammatory effects by inhibiting the COX-2 isoform. As compared to conventional NSAIDs, celecoxib, a COX-2 specific inhibitor, has been shown in previous single posttreatment endoscopy studies to be associated with lower gastroduodenal ulcer rates. In response to concerns that such studies may under-represent ulceration rates, the present serial endoscopy study was designed to compare cumulative gastroduodenal ulcer rates associated with the use of celecoxib to those of naproxen, a conventional NSAID. METHODS: In this double-blind, parallel-group, multicenter study, 537 patients with osteoarthritis (OA) or rheumatoid arthritis (RA) were randomized to treatment with celecoxib 200 mg b.i.d. (n = 270) or naproxen 500 mg b.i.d. (n = 267) for 12 wk. Gastroduodenal damage was determined from esophagogastroduodenoscopy after 4, 8, and 12 wk of therapy. Arthritis efficacy was evaluated with Patient's and Physician's Global Assessments. RESULTS: Gastroduodenal ulcer rates after celecoxib and naproxen treatment were 4% versus 19% in the 0-4 wk interval (p < 0.001), 2% versus 14% in the 4-8 wk interval (p < 0.001), and 2% versus 10% in the 8-12 wk interval (p < 0.001), respectively. After 12 wk of treatment, the cumulative incidence of gastroduodenal ulcers was 9% with celecoxib and 41% with naproxen. In the celecoxib group, gastroduodenal ulcers were significantly associated with Helicobacter pylori status (p < 0.05), concurrent aspirin usage (p = 0.001), and a history of ulcer (p = 0.010), but not with disease type (OA/RA), age, gender, other relevant medical histories, or concurrent corticosteroid or disease-modifying antirheumatic drugs usage (p > 0.05). Celecoxib produced a significantly lower incidence rate of both gastric (p < 0.001) and duodenal (p < 0.030) ulcers. The two agents produced similar improvements in Patient's and Physician's Global Assessments of arthritis efficacy. The incidence of adverse events and withdrawal rates did not differ significantly between treatments. CONCLUSIONS: As compared to naproxen (500 mg b.i.d.), use of celecoxib (200 mg b.i.d.), a COX-2 specific agent, at the recommended RA dose and twice the most frequently prescribed OA dose, was associated with lower rates of gastric, duodenal, and gastroduodenal ulcers but had comparable efficacy, in patients with OA and RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., & Seibert, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3228 · Cited by 1,310
Cited by
Pharmacological Management of Persistent Pain in Older Persons
American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02376.x · Cited by 1,008
Pharmacological Management of Persistent Pain in Older Persons
(2009) · Pain Medicine · doi:10.1111/j.1526-4637.2009.00699.x · Cited by 916
Chen, Y., Jobanputra, P., Barton, P., Bryan, S., Fry-Smith, A., Harris, G., & Taylor, R. (2008) · Health Technology Assessment · doi:10.3310/hta12110 · Cited by 339
Chan, F. K., To, K., Wu, J. C., Yung, M., Leung, W., Kwok, T., Hui, Y., Chan, H. L., Chan, C. S., Hui, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07272-0 · Cited by 329
Differences between clinical trials and postmarketing use
Martin, K., Bégaud, B., Latry, P., Miremont‐Salamé, G., Fourrier, A., & Moore, N. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01953.x · Cited by 157
Metadata
- Authors
- Goldstein, J. L., Corréa, P., Zhao, W. W., Burr, A. M., Hubbard, R. C., Verburg, K. M., & Geis, G.
- Venue
- The American Journal of Gastroenterology
- Publisher
- Lippincott Williams & Wilkins
- Published
- 2001-04-01
- Volume
- 96
- Issue
- 4
- Pages
- 1019-1027
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2039149640
- Cited by
- 199
- References
- 1
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced Incidence of Gastroduodenal Ulcers With Celecoxib, A Novel Cyclooxygenase-2 Inhibitor, Compared To Naproxen in Patients With Arthritis. https://app.cochat.ai/papers/10.1016/s0002-9270(01)02303-6
- The paper
- Goldstein, J. L., Corréa, P., Zhao, W. W., Burr, A. M., Hubbard, R. C., Verburg, K. M., & Geis, G. (2001). Reduced Incidence of Gastroduodenal Ulcers With Celecoxib, A Novel Cyclooxygenase-2 Inhibitor, Compared To Naproxen in Patients With Arthritis. The American Journal of Gastroenterology. https://doi.org/10.1016/s0002-9270(01)02303-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.